BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 37440251)

  • 1. Management of Down Syndrome-Associated Leukemias: A Review.
    Verma A; Lupo PJ; Shah NN; Hitzler J; Rabin KR
    JAMA Oncol; 2023 Sep; 9(9):1283-1290. PubMed ID: 37440251
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Leukemogenesis in infants and young children with trisomy 21.
    Roberts I
    Hematology Am Soc Hematol Educ Program; 2022 Dec; 2022(1):1-8. PubMed ID: 36485097
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The paradox of Myeloid Leukemia associated with Down syndrome.
    Gupte A; Al-Antary ET; Edwards H; Ravindranath Y; Ge Y; Taub JW
    Biochem Pharmacol; 2022 Jul; 201():115046. PubMed ID: 35483417
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hematological disorders in children with Down syndrome.
    Triarico S; Trombatore G; Capozza MA; Romano A; Mastrangelo S; Attinà G; Maurizi P; Ruggiero A
    Expert Rev Hematol; 2022 Feb; 15(2):127-135. PubMed ID: 35184659
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytogenetic features of acute lymphoblastic and myeloid leukemias in pediatric patients with Down syndrome: an iBFM-SG study.
    Forestier E; Izraeli S; Beverloo B; Haas O; Pession A; Michalová K; Stark B; Harrison CJ; Teigler-Schlegel A; Johansson B
    Blood; 2008 Feb; 111(3):1575-83. PubMed ID: 17971484
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent advances in the understanding of transient abnormal myelopoiesis in Down syndrome.
    Watanabe K
    Pediatr Int; 2019 Mar; 61(3):222-229. PubMed ID: 30593694
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transient Abnormal Myelopoiesis and AML in Down Syndrome: an Update.
    Bhatnagar N; Nizery L; Tunstall O; Vyas P; Roberts I
    Curr Hematol Malig Rep; 2016 Oct; 11(5):333-41. PubMed ID: 27510823
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term outcome for Down syndrome patients with hematopoietic disorders.
    Li MJ; Lee NC; Yang YL; Yen HJ; Chang HH; Chien YH; Lu MY; Jou ST; Lin KH; Hwu WL; Lin DT
    J Formos Med Assoc; 2016 Feb; 115(2):94-9. PubMed ID: 26234152
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Myeloid Proliferations Associated with Down Syndrome: Clinicopathologic Characteristics of Forty Cases from Five Large Academic Institutions.
    van den Akker TA; Liu YC; Liu H; Chapman J; Levine JM; Weinberg OK; Geyer JT
    Pathobiology; 2024; 91(1):89-98. PubMed ID: 36996802
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Down syndrome and malignancies: a unique clinical relationship: a paper from the 2008 william beaumont hospital symposium on molecular pathology.
    Xavier AC; Ge Y; Taub JW
    J Mol Diagn; 2009 Sep; 11(5):371-80. PubMed ID: 19710397
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PRAME immunohistochemical staining in transient abnormal myelopoiesis and myeloid leukemia associated with Down syndrome.
    Chisholm KM; Rivetta CV; Heerema-McKenney A
    Ann Clin Lab Sci; 2015; 45(2):121-7. PubMed ID: 25887863
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Landscape of driver mutations and their clinical effects on Down syndrome-related myeloid neoplasms.
    Sato T; Yoshida K; Toki T; Kanezaki R; Terui K; Saiki R; Ojima M; Ochi Y; Mizuno S; Yoshihara M; Uechi T; Kenmochi N; Tanaka S; Matsubayashi J; Kisai K; Kudo K; Yuzawa K; Takahashi Y; Tanaka T; Yamamoto Y; Kobayashi A; Kamio T; Sasaki S; Shiraishi Y; Chiba K; Tanaka H; Muramatsu H; Hama A; Hasegawa D; Sato A; Koh K; Karakawa S; Kobayashi M; Hara J; Taneyama Y; Imai C; Hasegawa D; Fujita N; Yoshitomi M; Iwamoto S; Yamato G; Saida S; Kiyokawa N; Deguchi T; Ito M; Matsuo H; Adachi S; Hayashi Y; Taga T; Saito AM; Horibe K; Watanabe K; Tomizawa D; Miyano S; Takahashi S; Ogawa S; Ito E
    Blood; 2024 Jun; 143(25):2627-2643. PubMed ID: 38513239
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Different drug sensitivity profiles of acute myeloid and lymphoblastic leukemia and normal peripheral blood mononuclear cells in children with and without Down syndrome.
    Zwaan CM; Kaspers GJ; Pieters R; Hählen K; Janka-Schaub GE; van Zantwijk CH; Huismans DR; de Vries E; Rots MG; Peters GJ; Jansen G; Creutzig U; Veerman AJ
    Blood; 2002 Jan; 99(1):245-51. PubMed ID: 11756178
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytogenetic and molecular study of 32 Down syndrome families: potential leukaemia predisposing role of the most proximal segment of chromosome 21q.
    Cavani S; Perfumo C; Argusti A; Pierluigi M; Perroni L; Schmiegelow K; Petersen MB; Cotter FE; Strigini P; Dagna-Bricarelli F; Nizetić D
    Br J Haematol; 1998 Oct; 103(1):213-6. PubMed ID: 9792310
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biology and management of transient abnormal myelopoiesis (TAM) in children with Down syndrome.
    Roy A; Roberts I; Vyas P
    Semin Fetal Neonatal Med; 2012 Aug; 17(4):196-201. PubMed ID: 22421527
    [TBL] [Abstract][Full Text] [Related]  

  • 16. GATA1 mutations in a cohort of Malaysian children with Down syndrome-associated myeloid disorder.
    Lum SH; Choong SS; Krishnan S; Mohamed Z; Ariffin H
    Singapore Med J; 2016 Jun; 57(6):320-4. PubMed ID: 27353457
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acute lymphoblastic leukemia in children with Down syndrome: a retrospective analysis from the Ponte di Legno study group.
    Buitenkamp TD; Izraeli S; Zimmermann M; Forestier E; Heerema NA; van den Heuvel-Eibrink MM; Pieters R; Korbijn CM; Silverman LB; Schmiegelow K; Liang DC; Horibe K; Arico M; Biondi A; Basso G; Rabin KR; Schrappe M; Cario G; Mann G; Morak M; Panzer-Grümayer R; Mondelaers V; Lammens T; Cavé H; Stark B; Ganmore I; Moorman AV; Vora A; Hunger SP; Pui CH; Mullighan CG; Manabe A; Escherich G; Kowalczyk JR; Whitlock JA; Zwaan CM
    Blood; 2014 Jan; 123(1):70-7. PubMed ID: 24222333
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Myeloid proliferations related to Down syndrome].
    Hasegawa D
    Rinsho Ketsueki; 2019; 60(9):1299-1307. PubMed ID: 31597856
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical impact of genomic characterization of 15 patients with acute megakaryoblastic leukemia-related malignancies.
    Lalonde E; Rentas S; Wertheim G; Cao K; Surrey LF; Lin F; Zhao X; Obstfeld A; Aplenc R; Luo M; Li MM
    Cold Spring Harb Mol Case Stud; 2021 Apr; 7(2):. PubMed ID: 33832921
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical and genetic features of pediatric acute lymphoblastic leukemia in Down syndrome in the Nordic countries.
    Lundin C; Forestier E; Klarskov Andersen M; Autio K; Barbany G; Cavelier L; Golovleva I; Heim S; Heinonen K; Hovland R; Johannsson JH; Kjeldsen E; Nordgren A; Palmqvist L; Johansson B; ; ;
    J Hematol Oncol; 2014 Apr; 7():32. PubMed ID: 24726034
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.